Molecular Diagnostics from Randox Biosciences
Our Randox Biosciences division is a trusted partner in supplying quality diagnostic solutions to the Clinical, Life Science, Pharmaceutical, Research and BioPharma industries.
Our molecular product range offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infections (STI), respiratory tract infection, colorectal cancer, familial hypercholesterolemia (FH) and cardiovascular disease (CVD).
Additionally, we can provide a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. The arrays are optimised for use with the Randox Evidence Investigator semi-automated, medium throughput bench-top biochip analyser.
One test, 10 results.
Our STI multiplex array II simultaneously detects 10 bacterial, viral and protozoan infections including primary, secondary and asymptomatic co-infections for a complete infection profile. The assay is based on a combination of multiplex, PCR and biochip array hybridisation. Innovative PCR priming technology permits high discrimination between multiple targets. A unique primer set is designed for each target which will hybridise to a complimentary oligo-nucleotide probe spotted on a biochip discrete test region (DTR).
The combination of priming and spatially organised biochip array technology enables enhanced specificity of the assay. Analysis can be completed from template DNA through PCR to data readout in less than 6 hours. The array is validated for urine and swab sample matrices with up to 53 patient samples being processed simultaneously. The array is CE marked for routine clinical use.
Our STI Multiplex Array II includes tests for the following STIs;
Neisseria Gonnorrhoea (NG) Mycoplasma Genitalium (MG)
Ureaplasma Urealyticum (UU) Chlamydia Trachhomatis (CT)
Tricomonas Vaginalis (TV) Haemophilus Ducreyi (HD)
Mycoplasma Hominis (MH) Treponema Pallidum (TP)
Herpes Simplex virus I (HSV-1) Herpes Simplex Virus 2 (HSV-2)
Randox Biosciences also offer four additional Molecular arrays.
For more information on our Molecular arrays please contact us by sending an email to Info@randoxbiosciences.com
Protecting Pets from the Threat of Mycotoxins
Pet Food companies worldwide are working towards constantly improving and maximising the quality of their product. The problematic topic of mycotoxin contamination in pet feed is quickly becoming a major cause for concern. This is due to the risk they pose for animal health and with the increasing prevalence of mycotoxins globally the focus is on pet food companies to meet EU and FDA regulations and maximise the quality of their product.
What are Mycotoxins?
Mycotoxins are naturally occurring metabolites that are produced by certain moulds and with the ability to develop and grow on a variety of crops they can affect large amounts of feed and increasingly, pet food. If a sample tests positive even for low levels of contamination the toxins are still strong enough to cause illness in animals, and if low levels are consumed over a long period of time this can result in chronic illnesses including; cancer, organ damage and neurological disorders.
The main mycotoxins of concern in pet food are;
- Deoxynivalenol (DON)
- Fumonisins (FUM)
- Zearalenone (ZEN)
- Aflatoxins
- Ochratoxin
- T-2 Toxin
Contamination can occur in any country around the world and at any stage of production. Herein lies the issue of how to prevent mycotoxin pollution, to tackle the issue head on and work towards a mycotoxin free product is the joint responsibility of feed producers, supply chain partners and quality control laboratories ensuring the complete safety of the product.
How can you tell if an animal has ingested pet food contaminated with mycotoxins?
In terms of animal health, mycotoxins can cause a variety of problems. Severity and symptoms can vary from animal to animal but general symptoms include; hyperactivity, vomiting, high temperature and loss of coordination. If you suspect your pet has been affected by mycotoxins you must bring them to the vet for immediate treatment.
The European Union currently regulate all the mycotoxins listed above and are subject to maximum or recommended residue limits. In the US, FDA regulations are limited to aflatoxins, DON and fumonisins, see table below for FDA regulations. If mycotoxin levels in feed fail to meet FDA standards, mass amounts of feed may need to be destroyed as grain producers are prohibited from mixing contaminated feed with clean feed to reduce the mycotoxin levels.
Pets | Mycotoxin | Commodity | Level |
Immature Animals | Aflatoxins | Corn/ peanut/ other ingredients | 20 ppb |
Adult Pets | Aflatoxins | Corn/ peanut/ cottonseed meal/ other ingredients | 20 ppb |
DON | Grain/ grain byproducts, not to exceed 40% of diet | 5 ppm | |
Fumonisins | Corn/ corn byproducts, not to exceed 50% of the diet | 10 ppm |
How do we tackle the problem?
Safe, reliable screening solutions for different variations of mycotoxins are available that can ensure only mycotoxin free feed is produced. Randox Food Diagnostics have created mycotoxin screening platforms as a response to increased levels of mycotoxins being found in feed globally.
The platforms use patented Biochip Array Technology (BAT) so pet food producers can test for multiple toxins from a single sample. Randox Food Diagnostics have a range of mycotoxin Biochip Arrays available with customised arrays available to suit the specific screening needs of certain producers. Each Biochip format uses a straightforward extraction process with a 50µl sample of feed, available tests include; Fumonisins, Ochratoxin A, Aflatoxin G1/G2, Aflatoxin B1, Paxiline, Ergot Alkaloids, Diacetoxyscirpenol, Deoxynivalenol, T2 Toxin and Zearalenone.
For more information on mycotoxin screening with Randox Food Diagnostics contact info@randoxfooddiagnostics.com
Powering the Evidence Series – Biochip Array Technology
In 2002, Randox invented a worlds first; Biochip Array Technology, instantly changing the landscape of diagnostic testing forever. Biochip Array Technology is a multi-analyte platform which provides an unrivalled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample.
How does it work?
Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The biochip detection system is based on a chemiluminescent reaction. This is the emission of light, without heat, as a result of a chemical reaction. An enzyme is used to catalyse the chemical reaction on the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge-Coupled Device (CCD) Camera.
Each biochip has up to 49 Discrete Test Regions (DTR). This means that up to 44 tests can be carried out simultaneously. The additional DTR are reserved for internal quality control and visual reference, a unique Biochip Array Technology feature.
How is the technology applied?
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user.
The Evidence Series has truly revolutionised diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
The Evidence Evolution: The world’s most advanced immunoassay analyser
What sets the Evidence Series apart from its competitors is its flexibility across the range of immunoassay analysers. No other range of analysers has the capability in terms of throughput in comparison to the Evidence Series. With this established, we are delighted to introduce the latest in the Evidence Series range, the Evidence Evolution.
Join the Evolution
We believe that the Evidence Evolution is the world’s most advanced immunoassay analyser. The Evidence Evolution is the most versatile analyser Randox has ever produced. By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Evolution can process up to 44 results from a single sample, with a maximum throughput of up to 2640 tests per hour. With such a high volume of potential throughput, you may think that reporting time will be compromised, that is simply not the case. The Evidence Evolution can produce the first set of results in less than 36 minutes, with one sample of up to 44 results reported every minute after. The speed of reporting time distinguishes the Evidence Evolution from its competitors, and allows the analyser to further display its capabilities.
Innovation
By utilising patented Biochip Array Technology, the Evidence Evolution offers batch analysis, true random access and STAT testing capabilities. These, combined with retrospective testing, allows the user to build a more in-depth patient profile.
With such swift reporting times, the Evidence Evolution can boast of a true walkaway time of 2 hours, in a laboratory setting, this can be vital. With multiple daily tasks to be completed, time is of the essence, and the Evidence Evolution has been designed to lessen the workload of laboratory staff. By being able to offer a combination of continuous sample and reagent loading, plus automated on-board sample dilution, the Evidence Evolution will have a positive impact in busy laboratories.
Complete Picture
A fast reporting time and high throughput capabilities is just the tip of what the Evidence Evolution can offer. The analyser has the capability to test across multiple matrices, allowing for more flexibility in sampling. It also comes equipped with state of the art intuitive software and advanced precision bio-drive robotics, meaning the Evidence Evolution is an analyser that has been designed and developed to meet the needs of a modern, high throughput laboratory, by a company that has a deep understanding of laboratory needs.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence Evolution, or any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Welcome to the Evidence Series
Introduction
For over 30 years, we have been researching and manufacturing market-leading diagnostics products globally. With a mission statement of ‘dedicated to improving health worldwide’ the patient needs are a central focus of everything we do. It is this experience and commitment to improving healthcare that has allowed us to continually improve our product offering and make advancements globally to reach as many people as possible and provide greater diagnostic facilities.
From this experience and commitment to research, we believe we have developed a technology that has changed diagnostic testing forever.
Biochip Array Technology
In 2002, we invented a world first, which changed the landscape of diagnostic testing forever. Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
An individual biochip has up to 49 Discrete Test Regions with each detecting a different biomarker. That means up to 44 tests can be carried out simultaneously, with the additional DTRs being reserved for visual quality control and visual reference; a feature unique to Biochip Array Technology.
The Evidence Series
Having developed this patented technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series. The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the brief overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities. For more information on any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Evidence Series Immunoanalysers
![Evidence banner - Purple](https://www.randox.com/wp-content/uploads/2019/06/Evidence-banner-Purple-scaled.jpg)
Powered by Biochip Array Technology
In 2002, Randox invented a world first, Biochip Array Technology (BAT), instantly changing the landscape of diagnostic testing forever. BAT is a multi-analyte platform which provides an unrivaled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample. So now the patient’s needs become the focus, as BAT delivers the multiple results needed for improved diagnosis.
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user. Utilising this technology, the Evidence series guarantees cost-effective, highly accurate and flexible testing solutions.
Why choose the Evidence Series?
Biochip Array Technology Test Menu
Adhesion Molecules
E-Selectin | P-Selectin | L-Selectin | |
Intercellular Adhesion Molecule-I – ICAM-I | Vascular Cell Adhesion Molecule-I –VCAM-I | ||
Alzheimer’s
Apolipoprotein E4 –ApoE4 | Pan Apolipoprotein E – Apo E |
Anaemia
Ferritin | Folate | Vitamin B12 |
Bone Disease
Vitamin D | |||
Cancer
Carcinoembryonic Antigen – CEA | Free Prostate Specific Antigen − FPSA | Total Prostate Specific Antigen − TPSA | |
Cardiac
Cardiac Troponin I – cTnl | Creatine Kinase MB – CKMB | Heart Fatty Acid Binding Protein – H-FABP | Myoglobin |
Cerebral
Brain-Derived Neurotrophic Factor − BDNF | Neuron Specific Enolase − NSE | ||
Cytokines
Epidermal Growth Factor − EGF | Granulocyte Macrophage Colony Stimulating Factor | Interferon-γ − IFN-γ | Interleukin-1 alpha − IL-1α |
Interleukin-1 beta − IL-1β | Interleukin-2 − IL-2 | Interleukin-3 − IL-3 | Interleukin-4 − IL-4 |
Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 | Interleukin-8 − IL-8 |
Interleukin-4 − IL-4 | Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 |
Interleukin-8 − IL-8 | Interleukin-10 − IL-10 | Interleukin-12p70 − IL-12p70 | Interleukin-13 − IL-13 |
Interleukin-15 − IL 15 | Interleukin-23 − IL-23 | Macrophage Infl ammatory Protein-1α − MIP-1α | Matrix Metalloproteinase 9 − MMP 9 |
Monocyte Chemotactic Protein-1 − MCP-1 | Soluble IL-2 Receptor Alpha − sIL-2Rα | Soluble IL-6 Receptor − sIL-6R | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 |
Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 | Tumour Necrosis Factor-α − TNF-α | Vascular Endothelial Growth Factor − VEGF | |
Diabetes
Insulin | |||
Endocrine
Cortisol | Dehydroepiandrosterone-Sulphate- DHEAS | ||
Fertility / Pregnancy
Estradiol | Follicle Stimulating Hormone − FSH | Luteinizing Hormone − LH | Progesterone |
Prolactin | Sex Hormone Binding Globulin − SHBG | Testosterone | |
Fibrinolysis
D-Dimer |
Gastro
Gastrin 17 – GI7 | Helicobacter pylori – H. pylori | Pepsinogen I – PGI | Pepsinogen II – PGII |
Metabolic
Adiponectin | Ferritin | Insulin | Leptin |
Plasminogen Activator Inhibitor − PAI-1 | Resistin |
Renal
Adiponectin | Complement C3a des Arginine – C3a des Arg | CRP (C-Reactive Protein) | Cystatin C |
D-Dimer | Epidermal Growth Factor − EGF | Fatty Acid Binding Protein-1 − FABP1 | Interleukin-8 − IL-8 |
Macrophage Infl ammatory Protein-1α − MIP-1α | Neutrophil Gelatinase – Associated Lipocalin – NGAL | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 |
Stroke
Brain-Derived Neurotrophic Factor − BDNF | D-Dimer | Glial Fibrillary Acidic Protein − GFAP | Glutathione S – Transferase Pi – GSTPi |
Heart Fatty Acid Binding Protein – H-FABP | Interleukin-6 − IL-6 | Nucleoside Diphosphate Kinase – NDKA | Neuron Specifi c Enolase − NSE |
Parkinson Protein 7 − PARK-7 | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | ||
Thyroid
Anti-Thyroglobulin − Anti-Tg | Anti-Thyroid Peroxidase − Anti-TPO | Free Tri-iodothyronine − FT3 | Free Thyroxine − FT4 |
Thyroid Stimulating Hormone − TSH | Thyroxine Binding Globulin − TBG | Total Tri-iodothyronine − TT3 | Total Thyroxine − TT4 |
Toxicology
Amphetamine | Barbiturates | Benzodiazepines I | Benzodiazepines II |
Buprenorphine | Cannabinoids – THC | Cocaine Metabolite | Dextromethorphan |
Fentanyl | Ketamine | Meprobamate | Methadone |
Opiate | Oxycodone I | Oxycodone II | Phencyclidine – PCP |
Tramadol | Tricyclic Antidepressants | Zolpidem | |
Molecular
20 SNPs | Adenovirus A/B/C/D/E | APOB – 1 mutation | Bordetella pertussis |
BRAF – 1 mutation | Chlamydia trachomatis – (CT) | Chlamydophila pneumoniae | Coronavirus 229E/NL63 |
Coronavirus OC43/HKU1 | Enterovirus A/B/C | Haemophilus ducreyi – (HD) | Haemophilus influenzae |
Herpes simplex Virus 1– (HSV-1) | Herpes simplex Virus 2 – (HSV-2) | Human Bocavirus 1/2/3 | Human Metapneumovirus – hMPV |
Influenza A/B | KRAS – 16 mutations | LDLR – 38 mutations | Legionella pneumophila |
Moraxella catarrhalis | Mycoplasma genitalium – (MG) | Mycoplasma hominis – (MH) | Mycoplasma pneumoniae |
Neisseria gonorrhoea – (NG) | Parainfluenza Virus 1/2/3/4 | PCSK9 – 1 mutation | PIK3CA – 3 mutations |
Respiratory Syncytial Virus a – RSVa | Respiratory Syncytial Virus b – RSVb | Rhinovirus A/B | Streptococcus pneumoniae |
Treponema pallidum – (TP) | Trichomonas vaginalis – (TV) | Ureaplasma urealyticum – (UU) | |
Veterinary Residues / Food Diagnostics
17β-Clostebol | 5-hydroxy Flunixin | Aflatoxin B1 | Aflatoxin G1/G2 |
Aflatoxin M1 | AHD | Amikacin/Kanamycin | Amino Benzimidazoles |
Amoxicillin | AMOZ | Amphenicols | Ampicillin |
AOZ | Apramycin | Avermectins | Bacitracin |
Baquiloprim | Benzimidazoles | Beta-agonists | Beta-Lactams |
Boldenone | Cefapirin | Cefoperazone | Cefquinome |
Ceftiofur | Cefuroxime | Cephalexin | Cephalonium |
Chloramphenicol | Chlormadinone | Clopidol | Cloxacillin |
Corticosteroids | Dapsone | Decoquinate | Deoxynivalenol |
Dexamethasone | Diacetoxyscirpenol | Diclazuril | Dicloxacillin |
Dihydrostreptomycin | Ergot Alkaloids | Erythromycin | Ethinylestradiol |
Fumonisins | Gentamicin | Gestagens | Halofugine |
Hygromycin B | Imidocarb | Kanamycin | Lasalocid |
Levamisole | Lincomycin | Lincosamides | MaduramicinG |
Melamine | Meloxicam | Metamizole | Methyltestosterone |
Monensin | Moxidectin (MXD) | Nandrolone | Neomycin/Paromomycin |
Nicarbazin | Nitroimidazoles | Nitroxynil | Novobiocin |
Ochratoxin A | Oxacillin | Paxilline | Penicillin G |
Penicillin V | Phenylbutazone | Pirlimycin | Polymixins |
Quinolones | Ractopamine | Rifaximin | Robenidine |
Salinomycin | SEM | Spectinomycin | Spiramycin |
Spiramycin/Josamycin | Stanozolol | Stilbenes | Streptomycin |
Sulfaguanidine | Sulfamethazine | Sulphachlorpyridazine | Sulphadiazine |
Sulphadimethoxine | Sulphadoxine | Sulphamerazine | Sulphamethazine |
Sulphamethizole | Sulphamethoxazole | Sulphamethoxypyridazine | Sulphapyridine |
Sulphaquinoxaline | Sulphathiazole | Sulphisoxazole | Sulphonamides |
T2 toxin | Tetracyclines | Thiabendazole | Thiamphenicol |
Tobramycin | Tolfenamic Acid | Toltrazuril | Trenbolone |
Triclabendazole | Trimethoprim | Tylosin | Tylosin B/Tilmicosin |
Virginiamycin | Virginiamycin M1 | Zearalenone | Zeranol |
Evidence Series Enquiry
Enquire to find out more about our Biochip powered Evidence Series immunoanalysers
We Are Randox | Tanya McKinty, Theater Choreographer turned R&D Scientist
Nerdy scientist by day but all singing all dancing performer by night – is there anything that Tanya McKinty can’t do?
Tanya works in the new state-of-the-art Randox Science Park as an R&D scientist but is also busy preparing for her roles as Lambeth landlady Mrs. Brown and Pearly Queen in the musical comedy ‘Me and My Girl.’
Tanya is performing this evening and the rest of the week (9th – 13th May) in the Grand Opera House and so we wanted to celebrate her talents and hard work with a feature piece on her personal musical story.
Good luck tonight Tanya!
Read on to find out how Tanya balances her scientific career and her passion for performing arts.
Hi Tanya, can you tell us a little bit about how you got started here in Randox?
I joined the company in 1993 after completing my PhD in Physical Chemistry and was involved in the early development work on the Randox biochips. But I have always loved studying so I did a Maths degree part time with the Open University and correspondence courses in spreadsheets, databases and VB programming. Now my official title is Data Analyst and I spend most of my time analysing data and devising problem-solving workbooks and macros for many departments throughout the company.
So how did you get into musical theatre given your strong background in Science and Maths?
I have been performing on stage since I was seven years old. My family was involved in ‘Those Who Care’ (TWC) which was a company set up by Tom McMurtry to provide entertainment to the staff and patients in Muckamore Abbey Hospital. They put on spring revue shows and Christmas pantomimes. I started as a dancer and then as I grew older I gradually began getting more acting roles. My first big acting role was when I was sixteen were I played the Fairy Godmother in Cinderella. After that I got involved with some of the amateur companies in Belfast that staged musicals.
I always had a great interest in dance and attended ballet and tap until I was 18. I took jazz, hip hop contemporary and musical theatre dance lessons as well. In 2013 I received my Diploma in Musical Theatre from the London College of Music. Since then I have taken part in a range of different acting workshops and play the piano occasionally. I was always more interested in music theory rather than music practice because I was quite mathematical. I reached grade five in theory and grade four in practice.
What do you do now in terms of acting?
Right now I am preparing to play the roles of Lambeth landlady Mrs. Brown and Pearly Queen in the musical comedy ‘Me and My Girl’. This is with St Agnes’ Choral Society and will take place in the Grand Opera House from the 9th-13th May. We have been rehearsing for past four months for it so I’m really looking forward to showcasing it to a public audience.
Can you tell us a bit about the preparation that has gone into ‘Me and My Girl’?
The early rehearsals involved learning all the music with our musical director. Most of the choral numbers are (at least) four part harmony and it’s important to get that drilled first so that when you start adding movement the harmonies are second nature and you only have to focus on what your feet are doing.
We then started learning the choreographed routines. There are some fast-paced numbers in this show so you really have to build up stamina to sing and dance at the same time. After that we start putting it all together with the dialogue scenes to learn where everything fits into place and when to make entrances and exits.
The week before the show is the most exciting but also the most exhausting. Stage manager, props team, sound and lighting all come along to rehearsals and we have the costume call where we get to see what the costumiers have sent over for us to wear. Then it’s into the Opera House for band call (singing with the full orchestra), tech rehearsal to mark scene changes and identify any technical issues and then dress rehearsal.
How did you get started with St Agnes’ Choral Society?
My friend was choreographing ‘Annie Get Your Gun’ for the company and they were short on dancers so she asked me to come in for the show. Everyone in the company was so friendly and welcoming and there was just a great family feel to it. So I auditioned to officially join the company and I haven’t looked back.
Can you tell us the names of any plays that you have starred in?
To date my two biggest roles have probably been Mrs Meers in ‘Thoroughly Modern Millie’ and Lorraine in ‘Boogie Nights’ which was a 70s musical. I’ve also had roles in ‘42nd Street’, ‘West Side Story’, ‘The Sound of Music’, ‘Hairspray’ and ‘9 to 5’ as well as others. My favourite character to play would be the villain or to have a good comedy role. I think Mrs Meers has been one of my favourite characters to play as she is a bit of both.
What has been the highlight of your time in St Agnes’ Choral Society to date?
By far the best highlight for me was being nominated as ‘Best Comedienne’ at the Association of Irish Musical Societies (AIMS). The AIMS has an adjudication scheme which considers all the musicals staged by amateur companies throughout Ireland. In June they have an awards weekend with a ceremony on the Saturday night very much in the style of the Oscars which is very glamorous. In 2011 I got nominated for my role as Mrs Meers. Although I didn’t win I still got an award for the mantelpiece, plus I didn’t have to make any acceptance speech which was a bonus I quite enjoyed.
Are there any upcoming plays happening after ‘Me and My Girl’?
Yes, we put on a show every year so the next one will be next year at some point. We haven’t announced which show yet but when it’s announced I’ll make sure to let you know. We perform an annual show in the Grand Opera House and then have a concert program for the rest of the year.
What do you enjoy most about acting in all of these plays?
I love reading and analysing a script to get an insight into a character. I also love telling a story no matter how complicated it is and experimenting with different ways to bring that character to life. I have worn an enormous fat suit and danced on a table, chased people around the stage with a (fake) shotgun and been the office drunk. But my favourite thing is working together with a team of people to give an audience an experience.
How did you get involved in choreographing shows throughout NI?
I started choreographing for the TWC because I had the most dance experience. I then joined Ulster Operatic and became dance captain (probably because I was the bossiest dancer!) and then started choreographing for them. After that I got approached by different companies to work with them.
What shows have you choreographed?
Lots! My favourites have been 42nd Street, High School Musical (I and II), Little Shop of Horrors, Seven Brides for Seven Brothers, Sister Act and Sunset Boulevard.
Do you have any other interests/hobbies outside of work?
I love to read if I can find time. My favourite genre would be historical novels.
What led you to pursue a career in science over acting?
I have always been a science geek! I got my first chemistry set when I was 11 and loved puzzles and problem-solving so I was always destined to be a scientist.
How do you manage your time between Randox and rehearsals?
Usually rehearsals are only once or twice a week so it’s not too bad. When we are rehearsing for a show our big rehearsals tend to be at the weekend. It can be exhausting but you get such a buzz from it that it’s worth it.
We’re so proud of Tanya and her commitment and dedication to her musical passion. We know she will do so well in the Grand Opera House this evening and can’t wait to hear how it goes!
Break a leg!
If you are interested in joining our global team make sure that you check out the Randox careers website to see what new opportunities we have for you.
#WeAreRandox
World Antibiotic Awareness Week at Randox
The global crisis of antimicrobial resistance is never far from the headlines. As part of World Amicrobial Awareness Week, we’ve been discussing the dangers and importantly the work being done to combat this growing threat.
There’s a very simple reason why we must all do what we can to tackle AMR. This year it’s thought 700,000 people died from drug resistant illnesses such as bacterial infections, malaria, HIV/Aids or tuberculosis. Experts warn that by 2050, this figure will rise to 10million.
Randox’s aim is to revolutionise global healthcare and we are committed to combating the threat of antibiotic resistance. We have a number of tests on the market that can help the fight against AMR, strengthen consumer confidence and ensure quality and safety for a number of different industries. So to round off this week, we spoke to two of our experts at Randox: Business Development Manager, Dr Mary Jo Kurth, and Molecular Diagnostics Manager, Dr Martin Crockard.
70% GP’s have been reported to prescribe antibiotics when they don’t know whether the infection is caused by the virus or bacteria.
At the frontline of the battle to curb AMR are the GPs but they’re not able to access the latest technology which can help them. Dr Mary Jo Kurth said, “In the current GP setting, diagnostic testing to determine whether a respiratory infection is bacterial or viral is unavailable, and therefore doctors often have to guess – or feel pressurised into prescribing antibiotics because patients demand it. However antibiotics only work to treat bacterial infections and are useless in treating infections that are caused by viruses.
“The consequences are severe. Medical procedures like organ transplantation and cancer chemotherapy need antibiotics to prevent and treat the bacterial infections that can be caused by the treatment. Without effective antibiotics, even routine operations could become high risk procedures if serious infections can’t be treated. The hard won victories against infectious diseases of the last fifty years will be jeopardized.”
Our Biosciences division have developed a test that can rapidly detect and identify the cause of 22 respiratory infections, in both the upper and lower respiratory tract, and therefore subsequently determine if an antibiotic is required as well as then identify the most effective antibiotic to take. Additionally our Confidante kit – the world’s first over-the-counter home sexual health test – can detect ten of the most common STIs with one patient sample and deliver accurate and reliable results securely and discreetly within one week. This takes the guesswork out of antibiotic prescription and could go a long way in fighting the antibiotic resistance crisis.
Dr Martin Crockard said, “Identifying the specific cause of illnesses provides opportunities to tailor treatment, reducing antibiotic misuse. Not all infections respond to antibiotics, however a multiplex approach which identifies bacterial, viral or fungal pathogens encourages improved clinical decision-making, refining treatment, leading to enhanced patient care.
“The molecular group here at Randox are developing a range of multiplex infection detection arrays to identify specific infection agents, allowing more appropriate use of antibiotics to improve patient care and reduce the onset of antibiotic resistance.”
In addition to tackling AMR via medical settings, there is work that can be done to deal with it in our food. Randox Food Diagnostics offer a comprehensive range of diagnostic solutions to allow for the detection and quantification of antibiotic residues within animal and food products. With validation across a range of matrices Randox Food allows producers to ensure their products are free from antibiotic residues.
As consumer awareness develops so does the need for antibiotic screening within agriculture and food production. Guaranteeing an antibiotic-free product strengthens consumer confidence and ensures food integrity on a global scale. Randox Food offers the Evidence Investigator matched with biochip array technology to provide the end user with fast, reliable results to ensure antibiotic free produce.
The UK Government recently commissioned a two year review into the crisis. Led by Lord Jim O’Neill, the final report outlined a new system of ‘market entry rewards’ worth $1.6 billion to the successful developer of a new antibiotic, which meets a prospectively-defined criteria of ‘unmet need’. Developers of alternative therapies aimed at tackling areas where there is unmet need due to rising AMR would also be eligible for these rewards. Such rewards would be paid after a successful product comes to market.
Chief Medical Officer, Dame Sally Davies said, “Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. That’s why governments and organisations across the world, including the World Health Organization and G8, need to take this seriously.
“This is not just about government action. We need to encourage more innovation in the development of antibiotics – over the past two decades there has been a discovery void around antibiotics, meaning diseases have evolved faster than the drugs to treat them.”
AMR will not go away on its own. It requires complex and comprehensive action across many sectors.
If you are interested in finding out more information, please visit randox.com
Randox and Chan Zuckerberg Initiative share common goal
You may have read in the news this week that the Chan Zuckerberg Initiative co-founded by Mark Zuckerberg has pledged to invest $3 billion over the next decade to help further and advance medical research. Investments will go towards a research facility, named the Biohub, which will focus on developing new tools to research, understand and treat diseases, and of particular interest to us here at Randox, on creating a chip to diagnose disease.
Here at Randox we fully support this drive to further research that is devoted to revolutionising healthcare. We commit up to 16% of turnover to research and development each year and currently over 20% of the world’s major laboratories are using Randox products.
In particular, we invested £220 million into the development of our Biochip Array Technology (BAT). The Randox biochip has revolutionised the diagnostics industry by facilitating the detection of a wide range of markers of disease from a single undivided sample. This not only enhances patient diagnosis but reduces the amount of time spent on individual tests and associated laboratory costs.
Our expertise, highly specialised scientists and world-class ISO accredited manufacturing facilities enables early, accurate, informed clinical decisions in the areas of veterinary testing, molecular research and diagnostics, drug development, food safety and forensic and clinical toxicology.
Our Randox Health clinics use our Biochip to allow people to avail of the complete portfolio of Randox routine and novel tests to empower their health decisions. This new and exciting service provides personalised and preventive health profiling for each individual.
Speaking about the biochip Dr. Peter FitzGerald, Founder and Managing Director of Randox said,
“Many years of development and the expertise of our highly qualified scientists have gone into the creation of Randox Biochip Array Technology. This scientific development will facilitate the simultaneous quantitative or qualitative detection of a wide range of analytes from a single undivided sample. This approach both proteomic and genomic enables an enhanced patient diagnosis, optimum efficiency and consolidation of cost. Our arrays are suitable for use in a wide range of settings including clinical and research laboratories, biopharmaceutical organisations, forensic and clinical toxicology, hospital laboratories, food testing and veterinary laboratories.”
We are delighted that Chan Zuckerberg’s interest in this area brings to the forefront the importance of improving healthcare through innovative diagnostics. It is clear that Randox and the Chan Zuckerberg Initiative share a common goal to revolutionise healthcare worldwide and we believe that the Randox Biochip can play an important role in realising this vision.
For further information please contact our Randox Comms Team on 028 9445 1016 or email amy.mcilwaine@randox.com